December 8, 2025BloodOpen Access

Infections in patients with relapsed refractory multiple myeloma receiving idecabtagene vicleucel therapy: A real-world analysis from CIBMTR

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Real-world analysis reveals high infection rates and significant risk factors impacting survival in patients receiving CAR T-cell therapy.

Infections developed in 28% of patients within 100 days post-CAR-T infusion, highlighting the infection burden.
The study identified significant risk factors, including Karnofsky performance score ≤80 and cytokine release syndrome grade ≥2.
Analysis utilized multivariable Cox proportional hazards models to examine infection outcomes and overall survival.
Results suggest that continued infection monitoring and prophylactic IVIG may improve outcomes in patients with multiple myeloma.

Abid et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Real-world analysis reveals high infection rates and significant risk factors impacting survival in patients receiving CAR T-cell therapy.